Protect Life's Moments
With GAMMAGARD LIQUID
[Immune Globulin Infusion (Human)]10%

  • Demonstrated tolerability across
    two routes of administration for PI patients1

    GAMMAGARD LIQUID offers two routes of administration for your patients - intravenous (IV) and subcutaneous (SC). Find out more about each, and about which might be the right decision for your patient.

    WARNING: THROMBOSIS, RENAL DYSFUNCTION and ACUTE RENAL FAILURE

    • Thrombosis may occur with immune globulin products, including GAMMAGARD LIQUID. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
    • Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients with immune globulin intravenous (IGIV) products including GAMMAGARD LIQUID. Renal dysfunction and acute failure occur more commonly with IGIV products containing sucrose. GAMMAGARD LIQUID does not contain sucrose.
    • For patients at risk of thrombosis, administer GAMMAGARD LIQUID at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

    Reference: 1. GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% [Prescribing Information]. Westlake Village, CA: Baxter Healthcare Corporation. April 2014.

    • GAMMAGARD LIQUID IV

      Find out more about GAMMAGARD LIQUID IV administration.
      See more
    • GAMMAGARD LIQUID SC

      Learn about SC administration of GAMMAGARD LIQUID.
      More info   Dosing   GAMMAGARD LIQUID SubQ CoPay Card
    • IV or SC?

      See the differences between IV and SC administration.
      Compare now
    • GAMMAGARD S/D (IV only)

      GAMMAGARD S/D IgA less than 1 ɥg/mL in a 5% solution for patients who require a low-IgA IV treatment. Find out more
    • Clinical Questions

      Find answers to common clinical questions. Get answers

You are now leaving GAMMAGARD.com

Shire is not responsible for the privacy policy, the content or the accuracy of any web site accessed through a link on the GAMMAGARD.com site. A link to other web sites does not constitute an endorsement of Shire of the linked site, its products or services.

The browser window or tab for GAMMAGARD.com will remain open underneath the new browser window or tab. To return to GAMMAGARD.com at any time, close this tab or window.

Return to
GAMMAGARD.com
Continue